Sumitomo Mitsui Trust Group Inc. Has $61.77 Million Stock Position in Masimo Co. (NASDAQ:MASI)

Sumitomo Mitsui Trust Group Inc. raised its position in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 0.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 373,705 shares of the medical equipment provider's stock after purchasing an additional 1,522 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 0.70% of Masimo worth $61,773,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in MASI. Calamos Advisors LLC acquired a new position in Masimo during the fourth quarter worth $2,691,000. Trust Point Inc. acquired a new stake in shares of Masimo in the fourth quarter valued at about $230,000. Greenleaf Trust acquired a new stake in Masimo in the 4th quarter valued at approximately $208,000. KBC Group NV grew its holdings in Masimo by 1,393.9% in the 4th quarter. KBC Group NV now owns 19,122 shares of the medical equipment provider's stock valued at $3,161,000 after buying an additional 17,842 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after buying an additional 71 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors and hedge funds.

Masimo Trading Up 0.0 %

Shares of MASI stock traded up $0.08 during trading hours on Thursday, reaching $179.59. The company had a trading volume of 290,031 shares, compared to its average volume of 455,387. The company has a 50 day moving average of $171.98 and a 200 day moving average of $148.54. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The firm has a market cap of $9.62 billion, a price-to-earnings ratio of 123.86 and a beta of 1.02. Masimo Co. has a 1-year low of $101.61 and a 1-year high of $183.14.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on MASI. Stifel Nicolaus reissued a "buy" rating and set a $190.00 target price (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Piper Sandler boosted their price target on Masimo from $180.00 to $210.00 and gave the company an "overweight" rating in a research note on Wednesday, December 18th. Wells Fargo & Company boosted their price target on shares of Masimo from $171.00 to $193.00 and gave the company an "overweight" rating in a research report on Wednesday, December 11th. Needham & Company LLC restated a "hold" rating on shares of Masimo in a research report on Wednesday, January 22nd. Finally, Raymond James boosted their target price on Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a report on Friday, December 27th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $191.40.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.